Tandem Diabetes Care | TNDM - Selling And Administration Expenses


Tandem Diabetes Care reported $99.86M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Accuray USD 127.32M 500.16M Sep/2025
Align Technology USD 441.68M 23.88M Dec/2025
AtriCure USD 78.34M 109K Dec/2025
Baxter International USD 761M 53M Dec/2025
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.83B 93M Dec/2025
Cooper Companies USD 419.2M 12M Sep/2025
Dexcom USD 299.9M 31.5M Dec/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Globus Medical USD 313.6M 9.98M Sep/2025
ICU Medical USD 155.81M 3.04M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 331.4M 16.2M Dec/2025
Integra LifeSciences USD 169.05M 10.84M Sep/2025
Intuitive Surgical USD 687.1M 113.8M Dec/2025
J&J USD 6.75B 831M Dec/2025
Masimo USD 116.4M 20.5M Sep/2025
Medtronic 2.97B 159M Sep/2025
Merit Medical Systems USD 107.38M 5.72M Sep/2025
Orthofix International USD 112.21M 1.1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Stryker USD 2.14B 150M Dec/2025
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 281.76M 66.68M Sep/2025
Zimmer Biomet Holdings USD 855.7M 44.3M Dec/2025